Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denileukin Diftitox in Stage IIIC and Stage IV Melanoma
NCT01127451Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2010
- Primary completion
- Apr 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of denileukin diftitox in melanoma, sponsored by Eisai Co., Ltd.. Started Jun 2010; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01127451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127451.